Lysophosphatidyl-choline 16:0 mediates persistent joint pain through Acid-Sensing Ion Channel 3: preclinical and clinical evidences
Preprint
Abstract
Rheumatic diseases are often associated to debilitating chronic joint pain, which remains difficult to treat and requires new therapeutic strategies. Here, we describe increased content of lysophosphatidyl-choline (LPC) 16:0 in the knee synovial fluids of two independent cohorts of patients with painful joint diseases. If LPC16:0 levels correlated with pain in patients with osteoarthritis (OA), they do not appear to be the hallmark of a particular joint disease. We found that intra-articular injections of LPC16:0 in mouse produce chronic pain and anxiety-like behaviors in both males and females with no apparent inflammation, peripheral nerve sprouting and damage, nor bone alterations. LPC16:0-induced persistent pain state is dependent on peripheral Acid-Sensing Ion Channel 3 (ASIC3), ultimately leading to central sensitization. LPC16:0 and ASIC3 thus appear as key players of chronic joint pain with potential implications in OA and possibly across others rheumatic diseases.Keywords
All Related Versions
- Published version: Pain, 163 (10), 1999.
This publication has 49 references indexed in Scilit:
- Lysophosphatidic acid receptors (LPARs): Potential targets for the treatment of neuropathic painNeuropharmacology, 2017
- Non‐acidic activation of pain‐related Acid‐Sensing Ion Channel 3 by lipidsThe EMBO Journal, 2016
- Lysoglycerophospholipids in chronic inflammatory disorders: The PLA2/LPC and ATX/LPA axesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013
- The Economic Costs of Pain in the United StatesThe Journal of Pain, 2012
- The impact of chronic pain—European patients’ perspective over 12 monthsScandinavian Journal of Pain, 2012
- The Roles of iPLA2, TRPM8 and TRPA1 in Chemically Induced Cold HypersensitivityMolecular Pain, 2010
- Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatmentEuropean journal of pain, 2006
- Initiation of neuropathic pain requires lysophosphatidic acid receptor signalingNature Medicine, 2004
- Regulation of Schwann Cell Morphology and Adhesion by Receptor-Mediated Lysophosphatidic Acid SignalingThe Journal of Neuroscience, 2001
- Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acidProceedings of the National Academy of Sciences, 1999